Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program.

Sartor O, Vogelzang NJ, Sweeney C, Fernandez DC, Almeida F, Iagaru A, Brown A Jr, Smith MR, Agrawal M, Dicker AP, Garcia JA, Lutzky J, Wong YN, Petrenciuc O, Gratt J, Shore ND, Morris MJ, U.S. Expanded Access Program Investigators

Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer: 3-Year Open Label Followup Results.

Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, Iversen P, Braeckman J, Heracek J, Baron B, Krivoshik A, Hirmand M, Smith MR

Nonmammalian Models of Huntington's Disease.

Chongtham A, Barbaro B, Filip T, Syed A, Huang W, Smith MR, Marsh JL

Activating Adult Allies From a Rural Community on Lesbian, Gay, Bisexual, Transgender, and Queer Student Issues in School Using Photovoice.

Hall WJ, Witkemper KD, Rodgers GK, Waters EM, Smith MR

Loss-of-function of neuroplasticity-related genes confers risk for human neurodevelopmental disorders.

Smith MR, Glicksberg BS, Li L, Chen R, Morishita H, Dudley JT

Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma, a Single-Institution Experience.

Sawalha Y, Hill BT, Rybicki LA, Sun D, Dean RM, Jagadeesh D, Hamilton BK, Gerds AT, Sobecks RM, Andresen S, Liu HK, Majhail NS, Pohlman B, Kalaycio ME, Bolwell BJ, Smith MR

Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet.

Armstrong AJ, Antonarakis ES, Taplin ME, Kelly WK, Beltran H, Fizazi K, Dahut WL, Shore N, Slovin S, George D, Carducci MA, Corn P, Danila D, Dreicer R, Heath E, Rathkopf D, Liu G, Nanus D, Stein M, Smith MR, Sternberg C, Wilding G, Nelson PS, Halabi S, Kantoff P, Clarke NW, Evans CP, Heidenreich A, Mottet N, Gleave M, Morris MJ, Scher HI

Analysis of Radionuclide Deposition Ratios from the Fukushima-Daiichi Incident.

Marianno CM, Smith MR, Cook KM

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY

Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era.

Mustafa Ali M, Rybicki L, Nomani L, Rouphail B, Dean RM, Hill BT, Jagadeesh D, Pohlman B, Hsi ED, Smith MR